Clinical Report: How to Increase Efficiency in Routine Oncology NGS Workflows

Overview

This report discusses the operational challenges in next-generation sequencing (NGS) workflows for precision oncology and presents findings from a comparative study of amplicon-based and hybrid-capture NGS workflows. The study highlights significant efficiency gains and cost-effectiveness of the amplicon-based Oncomine Dx Express Test.

Background

Next-generation sequencing (NGS) is pivotal in precision oncology, enabling tailored treatments for patients. As the demand for oncology testing rises, laboratories face increasing pressure to deliver accurate results efficiently. Addressing workflow inefficiencies is essential for maintaining quality and scalability in NGS testing.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The Oncomine Dx Express Test demonstrated greater efficiency and cost-effectiveness compared to hybrid-capture workflows.
• Redesigning NGS workflows can significantly reduce bottlenecks without compromising quality.
• Automation in NGS workflows can minimize manual touchpoints and shorten turnaround times.
• Operational challenges in NGS include complex workflows and resource constraints that hinder efficiency.
• Laboratory studies showed the importance of optimizing resources to accommodate increasing testing volumes.

Clinical Implications

Expand on how automation and workflow redesign can impact patient outcomes and laboratory scalability.

Conclusion

Improving efficiency in NGS workflows is vital for laboratories to keep pace with the rising demand for precision oncology. The findings underscore the importance of automation and workflow optimization in enhancing laboratory performance.

References

1. The analytical scientist, 2026 -- Five Tips for Optimizing Genomics Workflows
2. The pathologist, 2024 -- Building Consistency into NGS Workflows for Cancer Sample Profiling and More
3. Blood Cancer Journal -- Insights Gained from Next-Generation Sequencing in Blood Cancers
4. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025 - PubMed
5. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial | Nature Medicine
6. Codex Smoke Test Journal — Integrated Molecular Diagnostic Workflow Shortens Respiratory Pathogen Turnaround
7. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025 - PubMed
8. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial | Nature Medicine
9. Real-world clinical utility of tumor whole-genome sequencing in solid cancers - PMC